|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:actsOn
|
gptkb:REV-ERB_agonist
|
|
gptkbp:administeredBy
|
injection
oral
|
|
gptkbp:alsoKnownAs
|
gptkb:Stenabolic
|
|
gptkbp:CASNumber
|
1379686-30-2
|
|
gptkbp:category
|
research chemical
performance-enhancing drug (investigational)
nuclear receptor ligand
|
|
gptkbp:chemicalFormula
|
C20H24ClN3O4S
|
|
gptkbp:compatibleWith
|
gptkb:FDA
gptkb:EMA
human consumption
|
|
gptkbp:developedBy
|
gptkb:Scripps_Research_Institute
|
|
gptkbp:effectInMice
|
altered circadian behavior
altered lipid and glucose metabolism
increased exercise endurance
reduced fat mass
|
|
gptkbp:legalStatus
|
unregulated (research chemical)
|
|
gptkbp:mechanismOfAction
|
modulates REV-ERB nuclear receptors
|
|
gptkbp:relatedTo
|
SR9009
|
|
gptkbp:studiedBy
|
metabolic disorders
circadian rhythm regulation
potential athletic performance enhancement
|
|
gptkbp:target
|
NR1D1 (REV-ERBα)
NR1D2 (REV-ERBβ)
|
|
gptkbp:usedIn
|
gptkb:scientific_research
|
|
gptkbp:bfsParent
|
gptkb:State_Route_902
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
SR 902
|